

## IMI WEB-RADR project

EMA Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting 17-18 April 2018



Victoria Newbould, Surveillance and Epidemiology (P-PE-SVE) Pharmacovigilance and Epidemiology Department



#### **IMI WEBRADR**

- Response to IMI call in 2013
- Project Sep 2014- December 2017



Innovative Medicines Initiative

IMI-GB-DEC-2013-13 Annex 1

#### 9th Call for Proposals 2013

Innovative Medicines Initiative


Version 2

#### TABLE OF CONTENTS

GENE	RAL PRINC	JIPLES			
1	WEDVE	LEVEDACING	EMEDICING	TECHNOLOGY	EOD
1.	WEDAL -	LEVERAGING	EMERGING	TECHNOLOGY	FUR
	DHARMAC	OVIGILANCE			6
	LIMINIAC	OVIOIDANCE			



# Technology landscape WEBRADR focus on social media and health apps





## Outputs of WEB-RADR

Tasks divided across individual working groups





## **App for ADR reporting**

#### Promoting 2-way communication between Patients, HCPs and Regulators

Public (Patients, carers & HCPs)

**UK** 4000+ users

Netherlands 3400+ users

Croatia 695 users

**Burkina Faso & Zambia** 



iOS / Android mobile devices

#### National Competent Authorities

MHRA >400 reports

LAREB >150 reports


HALMED >130 reports

**DGPML/ZAMRA** [Recent launch]



## What does the App do?

#### Country specific branding



- Login: Ensure consent, data privacy and security
  - Mandatory login can be enabled/disabled
  - Country-specific configuration & colours
- Product Search: Search supported by suggestions
  - ⇒ Add product to personalised watchlist
  - ⇒ Deliver & display product specific news ('watch-list')
- News feed: reliable data provided by trusted source
  - Easily retrievable news of safety and risks
- Report side effects to the regulatory authority
  - Retrieve saved/previous submitted report



## Social media

- Pharmaceutical industry primarily use social media for commercial reasons
- Some use for 'Patient engagement' and recruitment into clinical trials

 Many examples of you tube videos from patients and HCP themselves and also from MAHs as part of educational aspects of Risk Minimisation




WEB-RADR has looked at social media for Pharmacovigilance

## RPA and machine learning

Terminology overload! Robotic Process Automation, machine learning, natural language processing, Big data analytics

Acquire → Process **Export** 





Relevant data are passed to another series of apps in preparation for human interpretation and





How to classify posts from social media in traditional PHV terms?






blind	doublevision	anorexic	lost appetite
blindness	googley eyed	apetite surpressed	lost my appetite
blurry		appetite is nonexistent	lost teh appetite
blurry vision changes in vision couldn't see cross vision	lost their eyesight seeing double	cant eat making can't eat or didn't get hungry	me eat like a mouse miss feeling hungry never hungry never want to eat #notevenhungry no appetitey
crosseyed	visión doble	killed my appetite	sin hambre
cross eyed	visual snow	lack of apetite	stomach small
MedDR <i>A</i> Visual ir	mpairment 3 10047571 mpairment 3 397540003	Decreased appetite MedDRA 10061428  Loss of appetite SNOMED 79890006	



#### Conclusions





## IMI-WEB RADR project – regulatory recommendations



- Objectives of IMI WEB-RADR work package 1 :
  - Assess the current regulatory framework
  - Prepare recommendations for consideration as part of future updates of GVP modules on the use of social media in support of pharmacovigilance taking into account results from the WEB-RADR social media analytics and evaluation work packages
  - Recommendations are to inform the EU Network's pharmacovigilance governance and future updates of Good Pharmacovigilance Practice (GVP) modules

## High level recommendations for policy

- Current guidance from GVP applies. In addition:
- No requirement to screen social media or follow up with users
- No requirement to create ICSRS from social media
- Social media can be used for signal detection as optional, any insights gained should be fed into the normal regulatory process (PSUR, RMP, Emerging safety Issue)
- Aspects should be defined and documented (such as purpose, choice of social media)
- Can also be used for non interventional studies, GVP applies and protocol required

## Project extension


#### Further development of the App:

Non interventional studies, Post Authorisation studies, Named Patient use

- Automated recognition of medicinal products for ADR reporting
  - Barcoding of packs
    - Include configurable batch # for biologicals/vaccines
    - Detection of fake, fraudulent, counterfeit medicines
  - Photographic identification based on images
    - Size, colour, shape and pattern recognition

## Project extension

- Communication
  - PIL, pack inserts, SmPC
  - aRMM (Education material, dosing cards)
- Establish links to other healthcare apps
  - Adherence to prescribed therapy
  - Diagnostic tests e.g. visual field test
  - Prognostic calculators,
  - Games to aid disease therapy and support
  - Patient Support Groups fora and information







## Thank you for your attention

#### Further information

<u>victoria.newbould@ema.europa.eu</u> <u>sabine.brosch@ema.europa.eu</u>

#### **European Medicines Agency**

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

Send a question via our website www.ema.europa.eu/contact Follow us on **@EMA\_News**